Collegium Pharmaceutical beats by $0.08, beats on revs
- Reports Q1 (Mar) loss of $0.57 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of ($0.65); revenues rose 2835.5% year/year to $63.7 mln vs the $51.92 mln Capital IQ Consensus.
- "In the first quarter of 2018, we were encouraged by the continued adoption of Xtampza ER by clinicians and payers," said Joe Ciaffoni, Chief Operating Officer of Collegium. "As we integrate the Nucynta franchise into our product portfolio, we are committed to providing comprehensive pain management options to people suffering with pain."
- Based on COLL's current operating plans, co believes that its existing cash resources, together with expected cash inflows from the commercialization of Xtampza ER and the Nucynta franchise will fund its operating expenses, debt service and capital expenditure requirements at least into 2020.
No comments:
Post a Comment